Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(4.68)
# 784
Out of 4,495 analysts
509
Total ratings
48.2%
Success rate
13.1%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterated: Buy | $20 | $13.97 | +43.22% | 24 | Jul 8, 2026 | |
| ATAI AtaiBeckley | Reiterated: Buy | $15 → $17 | $5.17 | +228.82% | 22 | Jul 7, 2026 | |
| HELP Cybin | Maintained: Buy | $45 → $42 | $6.23 | +574.16% | 23 | Jul 1, 2026 | |
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $32 → $36 | $26.00 | +38.46% | 52 | Jun 29, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $60 → $58 | $45.32 | +27.98% | 17 | Jun 29, 2026 | |
| BHVN Biohaven | Reiterated: Buy | $21 | $16.64 | +26.20% | 4 | Jun 18, 2026 | |
| ZVRA Zevra Therapeutics | Reiterated: Buy | $24 → $29 | $14.75 | +96.61% | 17 | Jun 11, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $27 | $3.41 | +691.79% | 20 | May 19, 2026 | |
| BIIB Biogen | Reiterated: Buy | $245 | $200.36 | +22.28% | 82 | May 15, 2026 | |
| CLNN Clene | Reiterated: Buy | $50 | $6.08 | +722.37% | 12 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 | $26.85 | +45.25% | 17 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $38.53 | -9.16% | 2 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $3.73 | +221.72% | 38 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $32.65 | +83.77% | 16 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $178.24 | +12.21% | 41 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $1.99 | +754.27% | 11 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $0.8022 | +2,143.83% | 55 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $120 → $36 | $5.00 | n/a | 10 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $75 → $12 | $17.25 | n/a | 12 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $34.63 | n/a | 4 | Apr 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $33.24 | n/a | 9 | Jan 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $66 → $53 | $16.66 | n/a | 8 | Nov 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $35 → $19 | $16.96 | n/a | 4 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $109 | $10.52 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $198.29 | $6.96 | n/a | 7 | Dec 18, 2015 |
COMPASS Pathways
Jul 8, 2026
Reiterated: Buy
Price Target: $20
Current: $13.97
Upside: +43.22%
AtaiBeckley
Jul 7, 2026
Reiterated: Buy
Price Target: $15 → $17
Current: $5.17
Upside: +228.82%
Cybin
Jul 1, 2026
Maintained: Buy
Price Target: $45 → $42
Current: $6.23
Upside: +574.16%
ACADIA Pharmaceuticals
Jun 29, 2026
Reiterated: Buy
Price Target: $32 → $36
Current: $26.00
Upside: +38.46%
Definium Therapeutics
Jun 29, 2026
Reiterated: Buy
Price Target: $60 → $58
Current: $45.32
Upside: +27.98%
Biohaven
Jun 18, 2026
Reiterated: Buy
Price Target: $21
Current: $16.64
Upside: +26.20%
Zevra Therapeutics
Jun 11, 2026
Reiterated: Buy
Price Target: $24 → $29
Current: $14.75
Upside: +96.61%
CervoMed
May 19, 2026
Reiterated: Buy
Price Target: $27
Current: $3.41
Upside: +691.79%
Biogen
May 15, 2026
Reiterated: Buy
Price Target: $245
Current: $200.36
Upside: +22.28%
Clene
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $6.08
Upside: +722.37%
May 15, 2026
Reiterated: Buy
Price Target: $39
Current: $26.85
Upside: +45.25%
May 15, 2026
Reiterated: Buy
Price Target: $35
Current: $38.53
Upside: -9.16%
May 11, 2026
Reiterated: Buy
Price Target: $12
Current: $3.73
Upside: +221.72%
May 8, 2026
Maintained: Buy
Price Target: $60
Current: $32.65
Upside: +83.77%
May 6, 2026
Reiterated: Buy
Price Target: $200
Current: $178.24
Upside: +12.21%
Apr 14, 2026
Reiterated: Buy
Price Target: $17
Current: $1.99
Upside: +754.27%
Sep 5, 2025
Reiterated: Buy
Price Target: $18
Current: $0.8022
Upside: +2,143.83%
Jun 12, 2024
Downgraded: Hold
Price Target: $120 → $36
Current: $5.00
Upside: n/a
Jan 28, 2022
Downgraded: Hold
Price Target: $75 → $12
Current: $17.25
Upside: n/a
Apr 9, 2018
Maintained: Hold
Price Target: n/a
Current: $34.63
Upside: n/a
Jan 31, 2017
Upgraded: Buy
Price Target: n/a
Current: $33.24
Upside: n/a
Nov 9, 2016
Reiterated: Buy
Price Target: $66 → $53
Current: $16.66
Upside: n/a
Nov 7, 2016
Reiterated: Sell
Price Target: $35 → $19
Current: $16.96
Upside: n/a
Jun 14, 2016
Reiterated: Sell
Price Target: $109
Current: $10.52
Upside: n/a
Dec 18, 2015
Maintained: Buy
Price Target: $198.29
Current: $6.96
Upside: n/a